OKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease
15 févr. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings
01 févr. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited- PDMR Dealing
27 janv. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited - Interim results for the six months to 30 September 2021
26 janv. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO) a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye...
OKYO Pharma announces issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease
14 déc. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease
13 déc. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
06 déc. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory...
OKYO Pharma Limited: Directorate Change
01 déc. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with...
OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
27 sept. 2021 07h17 HE
|
OKYO Pharma LTD
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye...
OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting
09 sept. 2021 02h00 HE
|
OKYO Pharma LTD
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...